Table II.

Clinical Trials Evaluating JAK/STAT3 and NF-κB Inhibition in Glioblastoma

Identifier	Intervention	Target/Pathway	Phase	Primary Outcome	Status
NCT01904123	WP1066	JAK2/STAT3	I	Maximum tolerated dose	Not yet recruiting
NCT01712542	Curcumin	STAT3 and others	0	Concentration of curcumin in tumor at time of surgery	Completed
NCT01654497	Dexanabinol	NF-κB and others	I	Maximum tolerated dose	Recruiting
NCT00306618	Panzem ®	NF-κB and others	II	6 month progression free survival and overall survival	Completed
NCT00481455	Panzem ® + TMZ	NF-κB and others; Chemotherapy	II	6 month progression free survival and overall survival	Completed
NCT00006773	Bortezomib	NF-κB and others;	I	Maximum tolerated dose	Terminated
NCT00544284	Bortezomib + TMZ	NF-κB and others; Chemotherapy	I	Maximum tolerated dose	Completed
NCT01435395	Bortezomib + Bevacizumab + TMZ	NF-κB and others; VEGF; Chemotherapy	I	Determination of progressive disease, complete or partial responses.	Recruiting
NCT00998010	Bortezomib + TMZ + Radiation	NF-κB and others; Chemotherapy	II	Overall survival at 2 years	Recruiting
NCT00611325	Bortezomib + Bevacizumab	NF-κB and others; VEGF	II	6 month progression free survival	Completed
NCT00108069	Bortezomib + Tamoxifen	NF-κB and others; SERM	II	Response – defined as stable disease or objective (partial or complete)	Completed
NCT00641706	Bortezomib + Vorinostat	NF-κB and others; HDAC	II	6 month progression free survival	Completed